Lexicon Pharmaceuticals (LXRX) EBIT (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly EBIT of -$996000.0 for Q1 2026, up 96.12% year-over-year from -$507848.9 in Q1 2025, and up 93.26% quarter-over-quarter from -$14.8 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) EBIT (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported EBIT for 17 consecutive years, with -$996000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 96.12% year-over-year to -$996000.0; the TTM figure through Mar 2026 stood at -$24.2 million (up 86.35% YoY), while the FY2025 annual figure was -$48.9 million, up 75.19% from the prior year.
- EBIT improved to -$996000.0 in Q1 2026 per LXRX's latest filing, from -$14.8 million in the prior quarter.
- Across five years, EBIT topped out at $3.7 million in Q2 2025 and bottomed at -$63.7 million in Q3 2024.
- Historically, EBIT has averaged -$30.6 million across 5 years, with a median of -$30.3 million in 2022.
- Annual changes were most pronounced in 2023 — EBIT tumbled 114.9% — and 2025, when it surged 106.75%.
- Lexicon Pharmaceuticals' EBIT stood at -$30.3 million in 2022, then sank by 54.36% to -$46.7 million in 2023, then advanced by 29.95% to -$32.7 million in 2024, then surged by 54.85% to -$14.8 million in 2025, then surged by 93.26% to -$996000.0 in 2026.
- Business Quant data shows LXRX's EBIT at -$996000.0 in Q1 2026, -$14.8 million in Q4 2025, and -$12.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -26.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.54 Mn |
| Mar 31, 2026 | -996,000.00 |
| Dec 31, 2025 | -14.78 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | -25.68 Mn |
| Dec 31, 2024 | -32.74 Mn |
| Sep 30, 2024 | -63.69 Mn |
| Jun 30, 2024 | -55.35 Mn |
| Mar 31, 2024 | -45.33 Mn |
| Dec 31, 2023 | -46.74 Mn |
| Sep 30, 2023 | -49.63 Mn |
| Jun 30, 2023 | -44.24 Mn |
| Mar 31, 2023 | -31.14 Mn |
| Dec 31, 2022 | -30.28 Mn |
| Sep 30, 2022 | -23.10 Mn |
| Jun 30, 2022 | -24.01 Mn |
| Mar 31, 2022 | -23.38 Mn |
| Dec 31, 2021 | -25.33 Mn |
| Sep 30, 2021 | -22.96 Mn |